H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Carisma Therapeutics (CARM) to $5 from $8 and keeps a Buy rating on the shares post the Q3 report. The firm says the CT-0525 data was pushed to Q1 of 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CARM:
- Carisma Therapeutics reports data from its CAR-M therapy
- Carisma Therapeutics reports Q3 EPS (31c), consensus (26c)
- Carisma to present new data on CAR-M therapy for hepatocellular carcinoma
- Carisma Therapeutics, Inc. (CARM) Q3 Earnings Cheat Sheet
- Leadership Transition at Carisma Therapeutics’ Board of Directors